(Q81780416)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18701330%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

title

Enzyme replacement therapy in Fabry disease: comparison of agalsidase alfa and agalsidase beta (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18701330%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

1 reference

Gere Sunder-Plassmann

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18701330%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

author name string

Atul Mehta

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18701330%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Michael Beck

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18701330%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Christoph Kampmann

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18701330%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Andrea Frustaci

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18701330%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Dominique P Germain

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18701330%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Gregory M Pastores

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18701330%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

publication date

12 August 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18701330%20AND%20SRC:MED&resulttype=core&format=json

Molecular Genetics and Metabolism

12 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18701330%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

volume

95

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18701330%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

issue

1-2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18701330%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

page(s)

114-115

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18701330%20AND%20SRC:MED&resulttype=core&format=json

Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3.

12 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.07.002

Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.07.002

A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.07.002

Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.07.002

Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.07.002

Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.07.002

Fabry disease: overall effects of agalsidase alfa treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.07.002

Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.07.002

Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.07.002

Agalsidase-beta therapy for advanced Fabry disease: a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.07.002

Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.07.002

Successful reinstitution of agalsidase beta therapy in Fabry disease patients with previous IgE-antibody or skin-test reactivity to the recombinant enzyme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.07.002

The pharmacology of multiple regimens of agalsidase alfa enzyme replacement therapy for Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.07.002

10.1016/J.YMGME.2008.07.002

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18701330%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

1 reference